Press release content from Business Wire. The AP news staff was not involved in its creation.
PhaseBio Reports Fourth-Quarter and Full-Year 2020 Financial Results and Recent Business Highlights
March 15, 2021 GMT
MALVERN, Pa. & SAN DIEGO (BUSINESS WIRE) Mar 15, 2021
PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today reported financial results for the fourth-quarter and full-year ended December 31, 2020 and provided an update on clinical trial activities.
ADVERTISEMENT
“Throughout 2020, PhaseBio made significant progress advancing our pipeline of therapies for serious cardiopulmonary diseases,” said Jonathan P. Mow, Chief Executive Officer of PhaseBio Pharmaceuticals. “Our progress was driven by the continued global expansion of the pivotal Phase 3 REVERSE-IT trial of our lead product candidate bentracimab, which has now enrolled m
San-diego
California
United-states
Canada
John-sharp
Alexc-sapir
Phasebio-pharmaceuticals-inc
Linkedin
Pulmonary-vascular-research-institute
Selenity-pharmaceuticals-bermuda-ltd
Nasdaq
Canale-communications-inc